DK1108034T3 - Svækkede salmonella SPI2-mutanter som antigenbærere - Google Patents
Svækkede salmonella SPI2-mutanter som antigenbærereInfo
- Publication number
- DK1108034T3 DK1108034T3 DK99946122T DK99946122T DK1108034T3 DK 1108034 T3 DK1108034 T3 DK 1108034T3 DK 99946122 T DK99946122 T DK 99946122T DK 99946122 T DK99946122 T DK 99946122T DK 1108034 T3 DK1108034 T3 DK 1108034T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell
- nucleic acid
- antigen
- acid molecule
- attenuated salmonella
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 108700008969 Salmonella SPI-2 Proteins 0.000 title 1
- 239000000969 carrier Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 101000823106 Equus caballus Alpha-1-antiproteinase 2 Proteins 0.000 abstract 2
- 210000005256 gram-negative cell Anatomy 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98116827 | 1998-09-04 | ||
PCT/EP1999/006514 WO2000014240A2 (en) | 1998-09-04 | 1999-09-03 | Attenuated salmonella sp12 mutants as antigen carriers |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1108034T3 true DK1108034T3 (da) | 2008-11-10 |
Family
ID=8232583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99946122T DK1108034T3 (da) | 1998-09-04 | 1999-09-03 | Svækkede salmonella SPI2-mutanter som antigenbærere |
Country Status (13)
Country | Link |
---|---|
US (3) | US6936425B1 (da) |
EP (2) | EP1970449B1 (da) |
JP (1) | JP2002524077A (da) |
AT (2) | ATE486940T1 (da) |
AU (1) | AU5860599A (da) |
BR (1) | BR9914479A (da) |
CA (1) | CA2341349C (da) |
CY (1) | CY1109387T1 (da) |
DE (2) | DE69939264D1 (da) |
DK (1) | DK1108034T3 (da) |
ES (2) | ES2313792T3 (da) |
PT (1) | PT1108034E (da) |
WO (1) | WO2000014240A2 (da) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ511170A (en) * | 1994-12-09 | 2005-02-25 | Imp College Innovations Ltd | Administering anitgens for protection against Salmonella infections |
AU5860599A (en) | 1998-09-04 | 2000-03-27 | Creatogen Aktiengesellschaft | Attenuated salmonella spi2 mutants as antigen carriers |
GB9910812D0 (en) * | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
AU2003204710B2 (en) * | 1999-05-10 | 2006-08-03 | Microscience Limited | Attenuated microorganisms for the treatment of infection |
EP1640013A3 (en) * | 2000-03-17 | 2007-02-21 | Pharmacia & Upjohn Company LLC | Inactivated Salmonella vaccines |
AU2001256957B2 (en) * | 2000-03-17 | 2005-08-25 | Pharmacia & Upjohn Company Llc | Salmonella vaccine materials and methods |
GB0105924D0 (en) * | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
US20040152099A1 (en) * | 2001-05-17 | 2004-08-05 | Elke Freissler | Screening method for attenuating or virulence defective microbial cells |
US8029777B2 (en) | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
US7968324B2 (en) * | 2004-08-13 | 2011-06-28 | Barry J Marshall | Helicobacter system and uses thereof |
CN1276076C (zh) * | 2004-12-14 | 2006-09-20 | 华东理工大学 | 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用 |
US20070134814A1 (en) * | 2005-12-09 | 2007-06-14 | Kajander E O | Methods and compositions for the detection of calcifying nano-particles, identification and quantification of associated proteins thereon, and correlation to disease |
DK2066339T3 (da) | 2006-09-18 | 2014-11-03 | Univ Arkansas | Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
WO2008141226A2 (en) * | 2007-05-10 | 2008-11-20 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens |
WO2009025888A2 (en) | 2007-05-10 | 2009-02-26 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety |
WO2008153772A2 (en) * | 2007-05-25 | 2008-12-18 | Emergent Product Development Gaithersburg Inc. | Chlamydia vaccine comprising htra polypeptides |
US8465755B2 (en) * | 2007-10-05 | 2013-06-18 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against enteric pathogens |
AU2008318615A1 (en) * | 2007-10-30 | 2009-05-07 | Texas A&M University System | Compositions and methods of enhancing immune responses to flagellated bacterium |
DK3097926T3 (da) * | 2007-11-01 | 2019-12-16 | Univ Arkansas | Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner på Eimeria |
US8703153B2 (en) | 2008-06-16 | 2014-04-22 | Prokarium Ltd. | Salmonella vectored vaccines against Chlamydia and methods of use |
EP2318515A4 (en) | 2008-08-06 | 2012-11-14 | Emergent Product Dev Uk Ltd | DIFFICULT CLOSTRIDIUM VACCINES, AND METHODS OF USE |
WO2010045620A1 (en) | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
US20120064114A1 (en) * | 2008-10-21 | 2012-03-15 | Emergent Product Development United Kingdom | Use of e. coli surface antigen 3 sequences for the export of heterologous antigens |
JP4575498B2 (ja) * | 2009-02-20 | 2010-11-04 | 株式会社東芝 | 磁気記録媒体の製造方法 |
US9163219B2 (en) * | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
WO2010141143A2 (en) * | 2009-04-21 | 2010-12-09 | Vivocure, Inc. | Engineered avirulent bacteria strains and use in medical treatments |
US8518658B1 (en) * | 2009-04-27 | 2013-08-27 | University Of South Florida | ATP-bioluminescence immunoassay |
WO2010135563A1 (en) * | 2009-05-22 | 2010-11-25 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium and methods of antigen and nucleic acid delivery |
US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
EA023058B1 (ru) | 2010-01-21 | 2016-04-29 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас | Вакцинные векторы и способы усиления иммунных ответов |
WO2011091291A1 (en) | 2010-01-22 | 2011-07-28 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID |
US9598697B2 (en) | 2010-05-28 | 2017-03-21 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
CA2800830C (en) | 2010-06-09 | 2020-09-08 | The Board Of Trustees Of The University Of Arkansas | Vaccine and methods to reduce campylobacter infection |
US8481052B2 (en) * | 2011-05-17 | 2013-07-09 | Cj Cheiljedang Corporation | Avirulent Salmonella gallinarum variants and pharmaceutical composition using the same |
RU2510839C2 (ru) * | 2012-05-03 | 2014-04-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Вакцина ассоциированная против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов |
RU2496518C1 (ru) * | 2012-05-03 | 2013-10-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | Способ изготовления вакцины ассоциированной против сальмонеллеза, эшерихиоза и вирусной геморрагической болезни кроликов |
US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
CN104470537B (zh) * | 2012-05-23 | 2017-04-26 | 美国政府(由卫生和人类服务部的部长所代表) | 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途 |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
PT2956165T (pt) | 2013-02-14 | 2019-11-29 | Texas A & M Univ Sys | Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria |
US10376571B2 (en) | 2013-03-15 | 2019-08-13 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to enteric pathogens |
WO2014144965A1 (en) * | 2013-03-15 | 2014-09-18 | Husseiny Elsayed Mohamed I | Attenuated salmonella bacteria and methods of using |
US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
US10987432B2 (en) * | 2013-09-05 | 2021-04-27 | The University Of Hong Kong | Therapeutic delivery and expression system, methods and uses thereof |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
KR20190015712A (ko) | 2016-05-03 | 2019-02-14 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
EP4045672A4 (en) * | 2019-10-18 | 2023-11-22 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR GENERATING ENHANCED IMMUNE RESPONSES AND RAPID ANTIBODIES PRODUCTION |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2022271976A1 (en) * | 2021-06-24 | 2022-12-29 | Elanco Us Inc. | Attenuated salmonella, vaccines, and delivery platform |
CN114292339B (zh) * | 2022-01-05 | 2022-08-09 | 武汉科前生物股份有限公司 | 鞭毛素突变体与非洲猪瘟抗原的融合蛋白及其应用 |
CN114703214A (zh) * | 2022-03-03 | 2022-07-05 | 南京吉芮康生物科技研究院有限公司 | 一种抗丢失时空可控表达的新型质粒及其应用 |
WO2024061748A1 (en) * | 2022-09-21 | 2024-03-28 | Prokarium Limited | Salmonella strain with chromosomally integrated landing pad |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US232165A (en) * | 1880-09-14 | Mechanical musical instrument | ||
US1449502A (en) * | 1921-04-23 | 1923-03-27 | James G Diffendaffer | Restraining device |
US1476164A (en) * | 1922-02-21 | 1923-12-04 | Michael J Manahan | Door and window shade and curtain clamp |
US1903387A (en) * | 1930-08-20 | 1933-04-04 | Eaton Mfg Co | Automobile heater |
US2103863A (en) * | 1936-12-28 | 1937-12-28 | Woodall Industries Inc | Visor construction |
US2728467A (en) * | 1954-01-28 | 1955-12-27 | Glicker Herman | Parking tower structure |
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
NO794196L (no) | 1978-12-22 | 1980-06-24 | Biogen Nv | Fremgangsmaate ved fremstilling av et rekombinert dna molekyl |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4837151A (en) | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US5210035A (en) | 1980-05-19 | 1993-05-11 | Board Of Trustees Of Leland Stanford Jr. University | Non-reventing live vaccines |
US4550081A (en) | 1980-05-19 | 1985-10-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Non-reverting salmonella |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US5397697A (en) | 1989-01-10 | 1995-03-14 | Ciba-Geigy Corporation | Identification of plant-responsive genes of bacteria |
FR2664614B1 (fr) | 1990-07-11 | 1992-10-16 | Pasteur Institut | Sequences nucleiques issues du genome de salmonella typhi, et leurs utilisations notamment pour le diagnostic in vitro de la presence de bacteries du genre salmonella dans les produits alimentaires. |
SE9101433D0 (sv) | 1991-05-13 | 1991-05-13 | Marianne Hansson | Recombinant dna sequence and its use |
WO1993004202A1 (en) | 1991-08-22 | 1993-03-04 | Washington University | Polynucleotide probes for salmonella |
WO1993007266A1 (en) | 1991-10-07 | 1993-04-15 | Idaho Research Foundation, Inc. | Genetic construct for selection of homologous recombinants on a single selective medium |
AU3130893A (en) | 1991-11-15 | 1993-06-15 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
US5356797A (en) | 1991-11-15 | 1994-10-18 | Board Of Regents, The University Of Texas | Membrane expression of heterologous genes |
JPH08503136A (ja) | 1992-11-06 | 1996-04-09 | リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ | P.multocidaによるパスツレラ症に対する感染防御剤 |
WO1994026933A1 (en) | 1993-05-13 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic footprinting: insertional mutagenesis and genetic selection |
AU3958895A (en) | 1994-10-18 | 1996-05-06 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
NZ511170A (en) | 1994-12-09 | 2005-02-25 | Imp College Innovations Ltd | Administering anitgens for protection against Salmonella infections |
US5700683A (en) | 1995-02-17 | 1997-12-23 | Pathogenesis Corporation | Virulence-attenuating genetic deletions deleted from mycobacterium BCG |
WO1997014800A1 (en) | 1995-10-16 | 1997-04-24 | Smithkline Beecham Plc | Novel saliva binding protein |
WO1997018225A1 (en) | 1995-11-14 | 1997-05-22 | The General Hospital Corporation | Salmonella secreted proteins and uses thereof |
WO1998006428A1 (en) | 1996-08-16 | 1998-02-19 | The Uab Research Foundation | Mucosal immunogens for novel vaccines |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
DE69828182T2 (de) | 1997-02-14 | 2005-12-22 | Merck & Co., Inc. | Polynukleotid-impfstoff-formulierungen |
US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
GB9804809D0 (en) | 1998-03-06 | 1998-04-29 | Wallis Timothy S | Attenuated salmonella:materials and methods relating thereto |
US6585975B1 (en) | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
AU5860599A (en) | 1998-09-04 | 2000-03-27 | Creatogen Aktiengesellschaft | Attenuated salmonella spi2 mutants as antigen carriers |
EP1129196B1 (en) | 1998-11-09 | 2008-01-09 | Microscience Limited | Virulence genes and proteins, and their use |
GB9910812D0 (en) | 1999-05-10 | 1999-07-07 | Microscience Ltd | Vaccine composition |
EP1226254A2 (en) | 1999-11-05 | 2002-07-31 | L'Unité de Recherche en Biologie Moléculaire (URBM) des Facultés Universitaires Notre Dame de la Paix (FUNDP) | Virulence genes, proteins, and their use |
WO2001048208A2 (en) | 1999-12-23 | 2001-07-05 | Vmax Limited | Streptococcus pyogenes virulence genes and proteins and their use |
GB0011108D0 (en) | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
GB0127657D0 (en) | 2001-11-19 | 2002-01-09 | Microscience Ltd | Virulence genes and proteins and their use |
US7449178B2 (en) | 2002-04-05 | 2008-11-11 | Merial Limited | Attenuated gram negative bacteria |
-
1999
- 1999-09-03 AU AU58605/99A patent/AU5860599A/en not_active Abandoned
- 1999-09-03 DE DE69939264T patent/DE69939264D1/de not_active Expired - Lifetime
- 1999-09-03 ES ES99946122T patent/ES2313792T3/es not_active Expired - Lifetime
- 1999-09-03 US US09/763,620 patent/US6936425B1/en not_active Expired - Fee Related
- 1999-09-03 DK DK99946122T patent/DK1108034T3/da active
- 1999-09-03 EP EP08075560A patent/EP1970449B1/en not_active Expired - Lifetime
- 1999-09-03 CA CA2341349A patent/CA2341349C/en not_active Expired - Fee Related
- 1999-09-03 AT AT08075560T patent/ATE486940T1/de not_active IP Right Cessation
- 1999-09-03 WO PCT/EP1999/006514 patent/WO2000014240A2/en active IP Right Grant
- 1999-09-03 BR BR9914479-4A patent/BR9914479A/pt not_active Application Discontinuation
- 1999-09-03 ES ES08075560T patent/ES2356863T3/es not_active Expired - Lifetime
- 1999-09-03 EP EP99946122A patent/EP1108034B1/en not_active Expired - Lifetime
- 1999-09-03 AT AT99946122T patent/ATE403728T1/de active
- 1999-09-03 DE DE69942925T patent/DE69942925D1/de not_active Expired - Lifetime
- 1999-09-03 JP JP2000568983A patent/JP2002524077A/ja active Pending
- 1999-09-03 PT PT99946122T patent/PT1108034E/pt unknown
-
2004
- 2004-01-23 US US10/763,883 patent/US7700104B2/en not_active Expired - Lifetime
-
2007
- 2007-08-17 US US11/840,928 patent/US7955600B2/en not_active Expired - Fee Related
-
2008
- 2008-11-06 CY CY20081101270T patent/CY1109387T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1108034A2 (en) | 2001-06-20 |
CA2341349C (en) | 2013-12-10 |
EP1970449A1 (en) | 2008-09-17 |
AU5860599A (en) | 2000-03-27 |
US7700104B2 (en) | 2010-04-20 |
DE69942925D1 (de) | 2010-12-16 |
WO2000014240A2 (en) | 2000-03-16 |
ES2313792T3 (es) | 2009-03-01 |
CY1109387T1 (el) | 2014-07-02 |
CA2341349A1 (en) | 2000-03-16 |
ATE403728T1 (de) | 2008-08-15 |
JP2002524077A (ja) | 2002-08-06 |
WO2000014240A3 (en) | 2000-08-03 |
EP1108034B1 (en) | 2008-08-06 |
US20080075739A1 (en) | 2008-03-27 |
US20040203039A1 (en) | 2004-10-14 |
DE69939264D1 (de) | 2008-09-18 |
PT1108034E (pt) | 2008-11-14 |
ATE486940T1 (de) | 2010-11-15 |
ES2356863T3 (es) | 2011-04-13 |
US6936425B1 (en) | 2005-08-30 |
US7955600B2 (en) | 2011-06-07 |
BR9914479A (pt) | 2001-06-26 |
EP1970449B1 (en) | 2010-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1108034T3 (da) | Svækkede salmonella SPI2-mutanter som antigenbærere | |
Amano et al. | Deficiency of peptidoglycan and lipopolysaccharide components in Rickettsia tsutsugamushi | |
BR9712971A (pt) | Método para produção de uma vacina para proteção de um hospedeiro contra doença causada com uma cadeia de chlamydia e composição imunológica | |
NZ316787A (en) | Methods and compositions for the selective modification of nucleic acids | |
NO960839L (no) | Bakterieeksporterte proteiner og acellulære vaksiner som er basert på disse | |
CY1107656T1 (el) | Εξασθενημενοι μικροοργανισμοι για την αντιμετωπιση μολυνσης | |
KR937000640A (ko) | 생 백신 | |
ATE143690T1 (de) | Cd40 kodierende dna | |
FI883722A0 (fi) | Alfa-amiderande enzymkompositioner och foerfaranden foer deras framstaellning och anvaendning. | |
FI960331A0 (fi) | Gandida utilis -hiivan transformointisysteemit ja vieraiden geenien ilmentäminen niiden avulla | |
AU2002314738A1 (en) | Methods for the production of products in host cells | |
Llama-Palacios et al. | Aggregatibacter actinomycetemcomitans growth in biofilm versus planktonic state: differential expression of proteins | |
DE69836520D1 (de) | Clostridium perfringens Impfstoff | |
IE810618L (en) | Pasteurella vaccines | |
DE68916424T2 (de) | Pasteurella-impfstoff. | |
DK0499681T3 (da) | pCTD-plasmid isoleret fra Chlamydia trachomatis serotype D, dets gener og proteiner, som kodes af dem; rekombinante plasmid | |
Kumar et al. | Outer membrane proteins of Fusobacterium necrophorum subsp. necrophorum and subsp. funduliforme | |
US20240042001A1 (en) | Irradiated whole-cell immunogens of acinetobacter baumannii | |
FI971402A0 (fi) | Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä sisältävien rokotteiden valmistamiseksi | |
DE69941099D1 (de) | Spezifische Nukleinsäuren und Polypeptide aus krankheitserregenden Stämmen von Neisseria | |
HU9900534D0 (en) | Aviadenovirus | |
McNeil et al. | Novel protease produced by a Pasteurella trehalosi serotype 10 isolate from a pneumonic bighorn sheep: characteristics and potential relevance to protection | |
O'HARA et al. | Mechanism of tetracycline resistance in Pseudomonas aeruginosa carrying an R factor | |
DK230890A (da) | Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m. | |
Jablonski et al. | Identification of Pasteurella multocida tryptophan synthase β-subunit by antisera against strain P1059 |